AcelRx to Host First Quarter 2021 Financial Results Call and Webcast on May 17, 2021

Rhea-AI Summary

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) will announce its first quarter financial results on May 17, 2021, after market close. A live conference call and webcast will follow at 4:30 p.m. ET, where management will discuss the financials and provide updates on the business. The webcast can be accessed via the company's website, along with a presentation. AcelRx specializes in developing innovative therapies for medically supervised settings, featuring products like DSUVIA® and Zalviso® for pain management.

Positive

• AcelRx has one approved product in the U.S., DSUVIA®, for pain management.
• Zalviso® is developed as a patient-controlled analgesia system aimed at reducing moderate-to-severe acute pain.

Negative

• Zalviso is still under investigation and not approved in the U.S.

HAYWARD, Calif., May 10, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Monday, May 17, 2021. AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 17, 2021 to discuss the financial results and provide an update on the company's business.

The webcast is accessible by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page. The webcast will be accompanied by a slide presentation.  A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at www.acelrx.com.

Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers, or (412) 902-4204 for international callers.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA®(sufentanil sublingual tablet, 30 mcg), known as DZUVEO™ in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg), being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is an investigational drug and not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-to-host-first-quarter-2021-financial-results-call-and-webcast-on-may-17-2021-301287807.html

SOURCE AcelRx Pharmaceuticals, Inc.

FAQ

When will AcelRx release its first quarter financial results for 2021?

AcelRx will release its first quarter financial results after market close on May 17, 2021.

What time is AcelRx's conference call on May 17, 2021?

The conference call will take place at 4:30 p.m. Eastern Time on May 17, 2021.

Where can I access the AcelRx Q1 2021 financial results webcast?

The webcast can be accessed on the Investors page of AcelRx's website.

What is AcelRx's main product for pain management?

AcelRx’s main product for pain management is DSUVIA® (sufentanil sublingual tablet), approved in the U.S.

Is Zalviso approved for use in the U.S.?

No, Zalviso is not approved in the U.S. and is still under investigation.